Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Authors:
Open Access
- 2 December 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 1068567
Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal mucosal inflammatory disease with complex etiology. Traditional anti-inflammatory treatment regimens have yielded unsatisfactory results. As research continues to deepen, it has been found that the gut microbiota of patients with IBD is generally altered. The presence of microorganisms in the human gastrointestinal tract is inextricably linked to the regulation of health and disease. Disruption of the microbiotic balance of microbiota in the gastrointestinal tract is called dysbiosis, which leads to disease. Therefore, in recent years, the exploration of therapeutic methods to restore the homeostasis of the gut microbiota has attracted attention. Moreover, the use of the well-established fecal microbiota transplantation (FMT) regimen for the treatment of Clostridioides difficile infection has attracted the interest of IBD researchers. Therefore, there are an increasing number of clinical studies regarding FMT for IBD treatment. However, a series of questions regarding FMT in the treatment of IBD warrants further investigation and discussion. By reviewing published studies, this review explored hot topics such as the efficacy, safety, and administration protocol flow of FMT in the treatment of IBD. Different administration protocols have generally shown reassuring results with significant efficacy and safety. However, the FMT treatment regimen needs to be further optimized. We believe that in the future, individual customized or standard FMT implementation will further enhance the relevance of FMT in the treatment of IBD.Keywords
This publication has 121 references indexed in Scilit:
- A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitisGut, 2013
- Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative ColitisInflammatory Bowel Diseases, 2013
- Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future DirectionsCurrent Gastroenterology Reports, 2013
- Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative ColitisJournal of Pediatric Gastroenterology and Nutrition, 2013
- Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's diseaseJournal of Gastroenterology and Hepatology, 2013
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic SyndromeGastroenterology, 2012
- Current and emerging drugs for the treatment of inflammatory bowel diseaseDrug Design, Development and Therapy, 2011
- Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relativesGut, 2011
- Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approachGut, 2005
- TREATMENT OF ULCERATIVE COLITIS BY IMPLANTATION OF NORMAL COLONIC FLORAThe Lancet, 1989